Previous 135 aircraft with excellent maintenance records, new exhaust per AD, October 2024 Annual, February 2025 IFR Certification. Low time engines Factory Reman engines (better than Overhauled).

The first few months of 2025 were full of graphics card reviews where we generally came away impressed with performance and completely at a loss on availability and pricing. The testing in these ...

Pradershika Sharma is a tech deals writer for Lifehacker. She has a Master’s degree in English Literature, a B.Ed., and a TESOL certification. She has been writing professionally since 2018, creating ...

The US government has cleared the possible sale of hundreds of Raytheon AIM-9X Sidewinder Block II air-to-air missiles to Denmark. The potential deal is valued at $319 million and covers 340 weapons, ...

The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan.

October 27, 2025 Add as a preferred source on Google Add as a preferred source on Google We may earn a commission from links on this page. Deal pricing and availability subject to change after time of ...

It began under a gray Oregon sky, the kind that smells faintly of rust and rain-soaked gasoline. When the barn doors groaned open, they revealed two Mopars from different galaxies of speed — a 1969 ...

Background: Emicizumab, a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis of bleeding episodes in people with hemophilia A, can impose a significant financial ...

Nephron Pharmaceuticals Corporation in West Columbia, South Carolina, from the air on Wednesday, April 9, 2025. Joshua Boucher [email protected] Nephron Pharmaceuticals, one of the largest ...

The 340B Drug Pricing Program was created to improve access to care for low-income and uninsured patients at safety-net hospitals and clinics. Over the years, however, critics have argued that the ...

TAO price drops 10% in a day after losing $360–$370, a key Fibonacci-based support zone. $340 emerges as the next critical level, with $323 and $285 as deeper downside targets if selling persists. A ...

On the heels of multiple lawsuits disrupting drug manufacturers’ efforts to convert the 340B Program into a rebate-based model, the Health Resources and Services Administration (HRSA) released a ...